stoxline Quote Chart Rank Option Currency Glossary
Caribou Biosciences, Inc. (CRBU)
7.91  -0.13 (-1.62%)    02-29 16:00
Open: 8.12
High: 8.18
Volume: 1,256,290
Pre. Close: 8.04
Low: 7.825
Market Cap: 699(M)
Technical analysis
2024-02-29 4:42:47 PM
Short term     
Mid term     
Targets 6-month :  9.72 1-year :  11.36
Resists First :  8.32 Second :  9.72
Pivot price 7.14
Supports First :  6.42 Second :  5.23
MAs MA(5) :  7.71 MA(20) :  7.03
MA(100) :  5.48 MA(250) :  5.37
MACD MACD :  0.4 Signal :  0.3
%K %D K(14,3) :  87.4 D(3) :  88.4
RSI RSI(14): 67.3
52-week High :  8.59 Low :  3.44
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ CRBU ] has closed below upper band by 12.1%. Bollinger Bands are 41.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 8.19 - 8.23 8.23 - 8.27
Low: 7.72 - 7.77 7.77 - 7.82
Close: 7.83 - 7.91 7.91 - 7.98
Company Description

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.

Headline News

Thu, 29 Feb 2024
Citigroup Inc. Acquires 194,816 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) - MarketBeat

Tue, 27 Feb 2024
Caribou Biosciences Inc (CRBU) Stock: What Does the Chart Say Tuesday? - InvestorsObserver

Mon, 26 Feb 2024
5 $10 Stocks That Will Triple - Insider Monkey

Mon, 26 Feb 2024
Where Does Caribou Biosciences Inc (CRBU) Stock Fall in the Biotechnology Field After It Has Risen 4.34% This Week? - InvestorsObserver

Fri, 23 Feb 2024
Steven Cohen's Point72 Adds Caribou Biosciences Inc to Its Portfolio - Yahoo Finance

Thu, 15 Feb 2024
Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 25% Share Price Surge Not Quite Adding Up - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 88 (M)
Shares Float 66 (M)
Held by Insiders 12.4 (%)
Held by Institutions 81.1 (%)
Shares Short 10,120 (K)
Shares Short P.Month 9,640 (K)
Stock Financials
EPS -1.43
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.5
Profit Margin -273.2 %
Operating Margin -61.9 %
Return on Assets (ttm) -16 %
Return on Equity (ttm) -26.2 %
Qtrly Rev. Growth 616.4 %
Gross Profit (p.s.) 0
Sales Per Share 0.39
EBITDA (p.s.) -1.2
Qtrly Earnings Growth 0 %
Operating Cash Flow -97 (M)
Levered Free Cash Flow -66 (M)
Stock Valuations
PE Ratio -5.54
PEG Ratio 0.4
Price to Book value 1.75
Price to Sales 20.21
Price to Cash Flow -7.22
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android